abstract
In this real-world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received corbopasvir (60 mg) and sofosbuvir (400 mg) daily for 12 weeks. The overall SVR12 was 99.1% (112/113). SVR12 was 100% for genotypes 3a, 3b, 6a, and compensated cirrhosis, 93.3% for genotype 1b, and 90% for HBV co-infection. Liver function (ALBI) and fibrosis scores (FIB-4, APRI) were significantly improved. No serious adverse events occurred. The corbopasvir + sofosbuvir regimen demonstrated excellent efficacy and safety across a variety of genotypes (including hard-to-treat genotype 3b) and comorbidities.
introduction
Chronic HCV is the main cause of liver cirrhosis and HCC in China. Genotype 3b is less responsive to some DAAs. Corbopasvir is a pan-genotypic NS5A inhibitor approved in China along with sofosbuvir. We need real-world data from eastern China.
method
Retrospective study at three centers (June 2023 to October 2024). Patients received corbopasvir (60 mg) + sofosbuvir (400 mg) for 12 weeks. Ribavirin was added for genotype 3 or cirrhosis. Primary endpoint: SVR12 (HCV RNA <15 IU/mL).
result
-
patient (N=113): median age 46 years, 84% male. Genotypes: 3 (58%; 3a 31%, 3b 27%), 6 (20%), 1b (13%). Cirrhosis 15%, HBV co-infection 9%, HIV 1%.
-
SVR12 rate: Overall 99.1% (112/113). 100% for genotypes 3a (35/35), 3b (30/30), 6a (23/23), compensated cirrhosis (17/17), HCC (1/1), hypertension (10/10), and diabetes (19/19). 93.3% (14/15) for genotype 1b; 90% (9/10) for HBV co-infection.
-
Improvement points: ALBI, FIB‑4 and APRI significantly decreased from baseline to EOT and SVR12 (all p<0.05).
-
safety: There were no serious adverse events. There are no cancellations due to AE. Common adverse events: headache, nausea, fatigue.
-
one failure: Genotype 1b + HBV co-infection did not reach SVR12.
discussion
This real-world study confirms high efficacy of corbopasvir + sofosbuvir (99.1% SVR12), including 100% in 30 genotype 3b patients, which is higher than that reported for sofosbuvir/velpatasvir (76%). This regimen also improved liver function and fibrosis markers. Limitations: Retrospective design, small HBV/HIV subgroup, no decompensated cirrhosis, limited long-term follow-up.
conclusion
Corbopasvir and sofosbuvir are highly effective and safe against chronic HCV in eastern China, including genotype 3b and patients with compensated cirrhosis or HBV co-infection. This is a valuable option for HCV removal.
sauce:
Reference magazines:
Luan, L.-M. Others. (2026). Practical efficacy and safety of cobropasvir and sofosbuvir in the treatment of chronic hepatitis C infection in Wenzhou, eastern China: a multicenter observational study. Journal of Clinical and Translational Hepatology. DOI: 10.14218/jcth.2025.00673. https://www.xiahepublishing.com/2310-8819/JCTH-2025-00673
